Andina Capital Management LLC Acquires Shares of 1,332 Johnson & Johnson (NYSE:JNJ)

Andina Capital Management LLC bought a new stake in Johnson & Johnson (NYSE:JNJ) in the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 1,332 shares of the company’s stock, valued at approximately $209,000.

A number of other large investors also recently made changes to their positions in the company. Massachusetts Wealth Management grew its holdings in Johnson & Johnson by 4.2% during the third quarter. Massachusetts Wealth Management now owns 16,105 shares of the company’s stock valued at $2,508,000 after purchasing an additional 650 shares during the period. Outfitter Financial LLC increased its holdings in Johnson & Johnson by 0.6% in the 3rd quarter. Outfitter Financial LLC now owns 16,857 shares of the company’s stock worth $2,625,000 after acquiring an additional 105 shares during the last quarter. Signet Investment Advisory Group Inc. raised its stake in Johnson & Johnson by 0.8% in the 3rd quarter. Signet Investment Advisory Group Inc. now owns 23,365 shares of the company’s stock valued at $3,639,000 after acquiring an additional 191 shares during the period. Bfsg LLC lifted its holdings in Johnson & Johnson by 6.4% during the third quarter. Bfsg LLC now owns 26,069 shares of the company’s stock valued at $4,060,000 after purchasing an additional 1,562 shares during the last quarter. Finally, Avestar Capital LLC increased its stake in shares of Johnson & Johnson by 12.1% in the third quarter. Avestar Capital LLC now owns 7,094 shares of the company’s stock worth $1,105,000 after purchasing an additional 763 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Trading Down 0.4 %

Shares of Johnson & Johnson stock opened at $149.27 on Monday. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.91. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $175.97. The firm has a market cap of $359.25 billion, a PE ratio of 9.31, a PEG ratio of 2.46 and a beta of 0.55. The company has a 50 day simple moving average of $154.19 and a two-hundred day simple moving average of $155.03.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. The company had revenue of $21.38 billion during the quarter, compared to the consensus estimate of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The firm’s revenue was up 2.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.68 EPS. Analysts expect that Johnson & Johnson will post 10.65 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.32%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date is Monday, May 20th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 29.68%.

Wall Street Analysts Forecast Growth

Several research firms recently commented on JNJ. Morgan Stanley cut their price objective on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a report on Wednesday, April 17th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a report on Monday, April 15th. Bank of America reduced their target price on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a report on Wednesday, April 17th. Finally, Royal Bank of Canada decreased their price target on Johnson & Johnson from $181.00 to $175.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 17th. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average price target of $175.86.

Insider Buying and Selling

In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the transaction, the insider now directly owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of the firm’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the sale, the executive vice president now owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder & Johnson Johnson sold 3,725 shares of the business’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the transaction, the insider now owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.